Inovio Pharmaceuticals (INO) Drops -17% Ahead of Pivotal FDA Decision
Key Takeaways
- Inovio Pharmaceuticals (INO) shares fell roughly 17% over the trailing 30 days, declining from about $1.32 to near $1.09.
- The pullback reflects a give-back of a sharp late-summer recovery rally as investors weigh the upcoming FDA decision on its lead candidate, INO-3107.
- The FDA's Prescription Drug User Fee Act (PDUFA) target action date for INO-3107 remains October 30, 2026, and accelerated-approval eligibility remains a key unresolved question.
- Dilution risk and a limited cash runway remain central concerns, with the company guiding cash into late first quarter 2027.
- Over the last quarter, the stock has traded with extreme volatility, including a sharp July drop tied to a public equity offering.
Inovio Pharmaceuticals (INO) Company Background
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing DNA medicines designed to treat and protect people from HPV-related diseases, cancer, and infectious diseases. Its platform combines precisely engineered DNA plasmids with a proprietary delivery device called CELLECTRA, which is intended to deliver genetic material into cells without chemical adjuvants or lipid nanoparticles.
The company's lead product candidate is INO-3107, an investigational treatment for recurrent respiratory papillomatosis (RRP), a rare and potentially life-threatening disease caused by HPV. Inovio's pipeline also includes VGX-3100, which targets cervical dysplasia, as well as next-generation DNA-encoded monoclonal antibody and DNA-encoded protein programs. I think investors follow the stock closely because the company's valuation is heavily tied to the regulatory and commercial outcome of INO-3107. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Inovio Pharmaceuticals (INO) Stock Price Performance Over the Past 30 Days and Quarter
Over the last 30 days, INO shares have fallen approximately 17%, moving from a closing price near $1.32 in early September to about $1.09 in early October. The decline has been relatively steady, with the stock shedding value through late September and into October as bullish momentum from late summer faded.
The broader quarterly picture is more volatile than the headline change suggests. Measured against levels near $1.19 in early July, the stock is down roughly 8% over the last three months. However, that figure masks a dramatic round trip: shares plunged to an intraday low near $0.57 and closed around $0.66 on July 30 following a dilutive public offering, then recovered to a peak near $1.45 in early September before retreating to current levels. The result is a stock that has been range-bound with sharp swings rather than trending decisively in one direction.
Factors Behind the Recent 30-Day Decline
The recent decline has been driven by a combination of profit-taking and renewed caution ahead of a pivotal regulatory catalyst. After the stock's sharp recovery from its July lows, investors have been reassessing the risk-reward profile as the October 30, 2026 PDUFA date approaches.
A key overhang is the FDA's stated position on accelerated approval. In its file-acceptance letter, the agency indicated a preliminary conclusion that Inovio had not submitted adequate information to justify eligibility for the accelerated approval pathway for INO-3107. While the company continues to believe it meets the criteria, this unresolved question has kept uncertainty elevated.
Balance-sheet concerns have also weighed on sentiment. Inovio ended the second quarter with $36.7 million in cash, cash equivalents, and short-term investments and has guided that current resources are expected to fund operations into late first quarter 2027. The company's history of dilutive equity offerings, including a July 2026 raise that added roughly 21 million shares, has left investors wary of additional capital raises.
Drivers of Performance Over the Full Quarter
The defining event of the quarter was the July 30, 2026 collapse tied to a public offering that generated approximately $18.3 million in net proceeds. The addition of more than 21 million shares triggered a sharp single-day selloff as existing shareholders absorbed the dilution.
The stock subsequently recovered, helped by a second-quarter earnings report in mid-August that showed a narrowed net loss of $6.0 million and declining operating expenses, alongside progress on INO-3107. Management confirmed that the FDA had completed its late-cycle review meeting and all scheduled pre-licensure inspections. Separately, partner ApolloBio announced positive top-line Phase 3 results for VGX-3100 in cervical dysplasia, supporting the broader DNA-medicine platform.
Despite these developments, the recovery stalled in September as attention shifted back to the regulatory uncertainty surrounding accelerated approval and the company's ongoing capital needs.
Key Catalysts to Monitor Going Forward
The most important near-term catalyst for INO is the FDA's action on the INO-3107 Biologics License Application, with a target action date of October 30, 2026. The outcome—and specifically whether the product receives accelerated approval—will have an outsized influence on the stock's direction.
Investors should also monitor Inovio's cash position and any signs of additional capital-raising activity, given the company's current runway into late first quarter 2027. Commercial execution will matter if INO-3107 is approved, including the ramp of the company's partnership with Syneos Health as its contract sales organization and early launch metrics against the already-marketed competitor Pepzimos. Finally, updates on VGX-3100's regulatory path in China and progress on the company's next-generation DNA medicine platform could shape the longer-term narrative. From what I see, these elements will likely dictate near-term moves.
AI Tools in My Research Process
When analyzing volatile biotech names like this one, I often rely on Tickeron’s AI Trading Bots to test systematic approaches alongside my own review of fundamentals and catalysts. These tools help scan for patterns across thousands of tickers and can surface strategies that align with short-term swings or longer trends. In practice, they serve as one more data point rather than a replacement for careful due diligence on regulatory timelines and balance-sheet risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INO in upward trend: price may jump up because it broke its lower Bollinger Band on September 14, 2026
INO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 43 cases where INO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +7.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 183 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 118 of 156 cases where INO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for INO moved out of overbought territory on September 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 15 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 79%.
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INO as a result. In 68 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for INO turned negative on September 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 36 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
INO moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.701) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of synthetic vaccines and immune therapies for cancers and infectious diseases
Industry Biotechnology
Advertisement